📰 Markc Schneyer News
Markc Schneyer News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Markc Schneyer. Real-time updates on events, politics, business and more.
June 4, 2024
Rafferty Asset Management LLC boosted its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 27.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 427,930 shares of the biopharmaceutical company’s stock after purchasing an additional 91,317 shares during the period. Rafferty […]
June 4, 2024
Rafferty Asset Management LLC boosted its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 27.1% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 427,930 shares of the biopharmaceutical company’s stock after purchasing an additional 91,317 shares during the period. Rafferty […]
May 29, 2024
Shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) have earned a consensus recommendation of “Moderate Buy” from the sixteen ratings firms that are currently covering the stock, Marketbeat reports. Four investment analysts have rated the stock with a hold rating and twelve have issued a buy rating on the company. The average twelve-month […]
May 29, 2024
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report)’s share price hit a new 52-week low during trading on Wednesday . The company traded as low as $14.60 and last traded at $14.68, with a volume of 628880 shares. The stock had previously closed at $15.09. Analyst Upgrades and Downgrades Several analysts recently weighed in on […]
May 29, 2024
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report)’s stock price reached a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $14.60 and last traded at $14.68, with a volume of 628880 shares traded. The stock had previously closed at $15.09. Analysts Set New Price Targets Several brokerages have […]
May 18, 2024
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) was the recipient of a significant growth in short interest in the month of April. As of April 30th, there was short interest totalling 12,030,000 shares, a growth of 7.8% from the April 15th total of 11,160,000 shares. Based on an average daily trading volume, of 1,810,000 […]
May 4, 2024
Cantor Fitzgerald restated their overweight rating on shares of ACADIA Pharmaceuticals (NASDAQ:ACAD – Free Report) in a report released on Tuesday morning, Benzinga reports. Cantor Fitzgerald currently has a $37.00 price objective on the biopharmaceutical company’s stock. A number of other equities research analysts have also recently commented on ACAD. Royal Bank of Canada decreased […]
April 23, 2024
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) shares hit a new 52-week low during mid-day trading on Tuesday . The company traded as low as $16.60 and last traded at $16.74, with a volume of 1475997 shares traded. The stock had previously closed at $16.99. Wall Street Analyst Weigh In ACAD has been the […]
April 18, 2024
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Get Free Report) was the recipient of a large increase in short interest in March. As of March 31st, there was short interest totalling 11,200,000 shares, an increase of 5.4% from the March 15th total of 10,630,000 shares. Based on an average daily volume of 1,830,000 shares, the days-to-cover ratio […]
April 5, 2024
China Universal Asset Management Co. Ltd. increased its stake in shares of ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD – Free Report) by 351.8% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 18,985 shares of the biopharmaceutical company’s stock after purchasing an additional 14,783 shares during the […]